Article
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
Lancet (London, England) - 24 Jan 2026
Lu Shun, Wang Jie, Yang Nong, Lv Dongqing, Chen Lijuan, Wu Lin, Li Xingya, Sun Longhua, Yu Yongfeng, Jin Bo, Yang Lin, Guo Yubiao, Xu Haipeng, Yi Tienan, Zeng Aiping, Dong Xiaorong, Chen Jianhua, Wang Ziping, Niu Hongrui, Cheng Ying, Pan Pinhua, Deng Pengbo, Pan Hongming, Min Xuhong, Bai Jun, Liu Laiyu, Zhang Tongmei, Li Juan, Fan Songhua, Shi Michael M, Mok Tony, Su Weiguo
Abstract excerpt
BACKGROUND: Savolitinib combined with osimertinib is a potential novel therapy for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) harbouring MET amplification after progression on EGFR tyrosine kinase inhibitor (TKI) therapy. We aimed to evaluate the efficacy and safety of savolitinib-osimertinib versus standard of care platinum-based doublet chemotherapy in this patient population....
Read the complete abstract on PubMedTopics
- Aged
- Female
- Humans